MA48709A - Conjugués de médicament à base de silicium et leurs procédés d'utilisation - Google Patents

Conjugués de médicament à base de silicium et leurs procédés d'utilisation

Info

Publication number
MA48709A
MA48709A MA048709A MA48709A MA48709A MA 48709 A MA48709 A MA 48709A MA 048709 A MA048709 A MA 048709A MA 48709 A MA48709 A MA 48709A MA 48709 A MA48709 A MA 48709A
Authority
MA
Morocco
Prior art keywords
conjugates
silicon
methods
medicinal products
based medicinal
Prior art date
Application number
MA048709A
Other languages
English (en)
Inventor
Kenneth W Foreman
Hanh Nho Nguyen
Leslie Odame Ofori
Jutta Wanner
Douglas S Werner
Original Assignee
Blinkbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blinkbio Inc filed Critical Blinkbio Inc
Publication of MA48709A publication Critical patent/MA48709A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/452—Block-or graft-polymers containing polysiloxane sequences containing nitrogen-containing sequences
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D183/00—Coating compositions based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon only; Coating compositions based on derivatives of such polymers
    • C09D183/04—Polysiloxanes
    • C09D183/08—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
    • C08G77/28—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen sulfur-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA048709A 2015-05-12 2016-05-12 Conjugués de médicament à base de silicium et leurs procédés d'utilisation MA48709A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160575P 2015-05-12 2015-05-12
US201562173002P 2015-06-09 2015-06-09

Publications (1)

Publication Number Publication Date
MA48709A true MA48709A (fr) 2020-04-08

Family

ID=57248538

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048709A MA48709A (fr) 2015-05-12 2016-05-12 Conjugués de médicament à base de silicium et leurs procédés d'utilisation

Country Status (7)

Country Link
US (3) US9931407B2 (fr)
EP (1) EP3294810A4 (fr)
JP (3) JP6987641B2 (fr)
AU (3) AU2016262107B2 (fr)
CA (1) CA2985823A1 (fr)
MA (1) MA48709A (fr)
WO (1) WO2016183359A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985823A1 (fr) 2015-05-12 2016-11-17 Blinkbio, Inc. Conjugues de medicament a base de silicium et leurs procedes d'utilisation
MX381031B (es) * 2015-08-11 2025-03-12 Coherent Biopharma | Ltd Conjugados fármaco-multiligando y usos de los mismos.
EP3423112A4 (fr) * 2016-02-29 2020-02-26 Madrigal Pharmaceuticals, Inc. Conjugués de type inhibiteur de hsp90-médicament
WO2017214491A1 (fr) 2016-06-09 2017-12-14 Blinkbio, Inc. Charges utiles thérapeutiques à base de silanol
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2019001550A1 (fr) * 2017-06-30 2019-01-03 北京键凯科技股份有限公司 Derive de polyéthylèneglycol multibranche, à terminaison à plusieurs ramifications, utilisé dans des réactions de chimie click
CN109206610B (zh) * 2017-06-30 2020-06-30 北京键凯科技股份有限公司 一种适用于点击化学反应的多臂多爪聚乙二醇衍生物
JP2020525591A (ja) * 2017-07-06 2020-08-27 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ シリコーン化合物
US12065458B2 (en) 2018-02-17 2024-08-20 Arrowhead Pharmaceuticals, Inc. Trialkyne linking agents and methods of use
CA3089276A1 (fr) * 2018-02-17 2019-08-22 Arrowhead Pharmaceuticals, Inc. Agents de liaison trialcyne et procedes d'utilisation
TWI705813B (zh) 2019-05-24 2020-10-01 國立交通大學 含有ganetespib的粒子與含有該粒子的藥學組成物及其在抗癌治療上的用途
JP7310894B2 (ja) * 2019-08-09 2023-07-19 信越化学工業株式会社 第１級アミノシロキサン化合物の製造方法
JP2021028321A (ja) * 2019-08-09 2021-02-25 信越化学工業株式会社 アミノ基含有有機ケイ素化合物の製造方法
CN110922551B (zh) * 2019-10-29 2021-09-14 温州大学 一种用于铁离子检测的罗丹明-聚氨酯荧光探针的制备方法
ES2963150T3 (es) 2020-10-27 2024-03-25 Elucida Oncology Inc Procedimientos para funcionalizar nanopartículas
CN112940044B (zh) * 2021-02-04 2023-07-04 厦门大学 一种黄连素偶联顺铂化合物及其制备方法和应用
WO2022272307A1 (fr) * 2021-06-24 2022-12-29 Lycia Therapeutics, Inc. Composés bifonctionnels de liaison au récepteur des folates
KR20240154017A (ko) 2022-02-22 2024-10-24 에이디씨 테라퓨틱스 에스에이 트리밍된 n-글리칸을 포함하는 fc 영역에서 트랜스글루타미나제를 포함하는 접합 방법
US20250295788A1 (en) * 2022-05-04 2025-09-25 The Trustees Of The University Of Pennsylvania Siloxane-based lipids, lipid nanoparticle compositions comprising the same, and methods of use thereof for targeted delivery
WO2025254796A1 (fr) * 2024-06-04 2025-12-11 Dow Global Technologies Llc Composés d'organosilicium à fonction amine cyclique et leur synthèse

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0918069B1 (fr) 1997-05-30 2008-04-09 Shiseido Company Limited Compositions contenant un copolymere aux groupes silyles reactifs et methodes de leur emploi
CN100349963C (zh) * 2002-12-30 2007-11-21 尼克塔治疗亚拉巴马公司 作为药物输送媒介物的多分支多肽－聚(乙二醇)嵌段共聚物
CN101952719A (zh) 2007-07-27 2011-01-19 通信改革公司 检测测定法及其用途
US7687496B2 (en) 2007-10-16 2010-03-30 Bionumerik Pharmaceuticals, Inc. C7-substituted camptothecin analogs
WO2009051580A1 (fr) 2007-10-16 2009-04-23 Bionumerik Pharmaceuticals, Inc. Analogues de camptothécine substitués en c7
ES2396366T3 (es) 2007-12-10 2013-02-21 Concert Pharmaceuticals Inc. Inhibidores heterocíclicos de quinasas
US8853185B2 (en) 2008-04-09 2014-10-07 Cornell University Coferons and methods of making and using them
US20120045396A1 (en) * 2009-01-15 2012-02-23 Board Of Regents Of The University Of Texas System Porous structures with modified biodegradation kinetics
CN102574866B (zh) 2009-06-17 2015-02-18 四川恒康发展有限责任公司 喜树碱衍生物
CA2774476A1 (fr) 2009-10-07 2011-04-14 Francis Barany Coferons et procedes de fabrication et d'utilisation de ceux-ci
WO2012092339A2 (fr) * 2010-12-28 2012-07-05 The Children's Hospital Of Philadelphia Conception de promédicaments libérables par hydrolyse pour des formulations de nanoparticules à libération prolongée
WO2013058825A1 (fr) 2011-04-07 2013-04-25 Cornell University Monomères silyles aptes à former un multimère dans une solution aqueuse et leurs procédés d'utilisation
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
WO2012139134A2 (fr) 2011-04-07 2012-10-11 Coferon, Inc. Procédés de modulation des protéines de fusion oncogènes
WO2012154213A1 (fr) 2011-04-07 2012-11-15 Cornell University Cofluorons et leurs procédés de fabrication et d'utilisation
WO2013033269A1 (fr) 2011-08-29 2013-03-07 Coferon, Inc. Monomères bioorthogonaux capables de se dimériser et de cibler des bromodomaines et procédés d'utilisation correspondant
WO2013033270A2 (fr) 2011-08-29 2013-03-07 Coferon, Inc. Ligands de brodomaines capables de se dimériser dans une solution aqueuse, et procédés d'utilisation de ceux-ci
KR20150119848A (ko) * 2012-12-21 2015-10-26 바이오얼라이언스 씨.브이. 친수성 자기-희생 링커 및 그것의 포합체
EP2968599A4 (fr) * 2013-03-14 2016-11-09 Albany Molecular Res Inc Conjugués ligand-agent thérapeutiques et lieurs à base de silicium
US20150080570A1 (en) 2013-04-11 2015-03-19 Coferon, Inc. Alpha,beta-unsaturated monomers capable of multimerization in an aqueous solution, and methods of using same
US20150087043A1 (en) 2013-04-11 2015-03-26 Coferon, Inc Monomers capable of multimerizing in an aqueous solution that employ bioorthogonal chemistries, and methods of using same
CA2985823A1 (fr) 2015-05-12 2016-11-17 Blinkbio, Inc. Conjugues de medicament a base de silicium et leurs procedes d'utilisation
WO2017214491A1 (fr) 2016-06-09 2017-12-14 Blinkbio, Inc. Charges utiles thérapeutiques à base de silanol

Also Published As

Publication number Publication date
AU2016262107A1 (en) 2017-11-30
JP2018528156A (ja) 2018-09-27
JP7195402B2 (ja) 2022-12-23
JP2022028904A (ja) 2022-02-16
US20170202970A1 (en) 2017-07-20
AU2016262107B2 (en) 2021-01-21
US20190290771A1 (en) 2019-09-26
AU2023203341A1 (en) 2023-06-22
US20230000993A1 (en) 2023-01-05
JP6987641B2 (ja) 2022-01-05
EP3294810A4 (fr) 2019-01-02
EP3294810A1 (fr) 2018-03-21
US9931407B2 (en) 2018-04-03
US11291731B2 (en) 2022-04-05
WO2016183359A1 (fr) 2016-11-17
JP2023021283A (ja) 2023-02-10
CA2985823A1 (fr) 2016-11-17
AU2021202329A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
MA45280A (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3436061A4 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
EP3630199A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630788A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630789A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3493676A4 (fr) Compositions antimicrobiennes à base de polymère et leurs procédés d'utilisation
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3416634A4 (fr) Agents immunomodulateurs et leurs procédés d'utilisation
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
EP3341027A4 (fr) Complexes de transfection et leurs procédés d'utilisation
EP3314218A4 (fr) Distributeurs de dose mesurée et leurs procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3380525A4 (fr) Formulations pharmaceutiques et leurs procédés d'utilisation
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3302558A4 (fr) Agents anticancéreux et procédés d'utilisation